PharmaCyte Biotech to Change Future of Treating Diseases with Validation of Encapsulation Technology in Pancreatic Cancer Trial
Written by Ι Stock Market Media — October 28, 2019
PharmaCyte Biotech (OTCQB: PMCB) has a technology that could very well change the way a host of hard-to-treat diseases are treated for the foreseeable future. The company is closer than ever to its upcoming Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC) that could give patients a new lease on life by shrinking their tumors enough so that the tumors can be removed surgically. It is an outcome that would ...
Read More →
28
OCT
Share
PharmaCyte Biotech Closer to Submitting IND with Successful Completion of Clinical Trial Product
Written by Ι Stock Market Media — October 16, 2019
NEW YORK, NY, Oct. 16, 2019 — PharmaCyte Biotech (OTCQB: PMCB) has now moved one step closer to submitting an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) to request a clinical trial in locally advanced, inoperable pancreatic cancer (LAPC) in the United States. The company has successfully completed the first of two manufacturing runs to produce the clinical trial product (Cell-in-a-Box® capsules) it needs for ...
Read More →
16
OCT
Share
PharmaCyte Biotech Nearing Major Milestone—An Open IND with the FDA
Written by Ι Stock Market Media — February 4, 2019
Clinical stage biotechnology company PharmaCyte Biotech (OTCQB: PMCB) is now closer than ever to reaching what would be a monumental milestone in the company’s history. Years of patience from PharmaCyte’s shareholders has now likely been whittled down to what should now be just months, and with the condensed timeline, the company is this close to what will be a landmark event—an “open” or approved Investigational New Drug application (IND) with the U.S. ...
Read More →
4
FEB
Share
World-Renowned Oncologist Bullish on Potential of PharmaCyte’s Technology, Clinical Trial in Pancreatic Cancer
Written by Ι Stock Market Media — January 23, 2019
“I am excited about this new approach that has the potential to change the way solid tumors are treated far beyond tumors in the pancreas.”
NEW YORK, NY – With PharmaCyte Biotech, Inc.’s (OTCQB: PMCB) naming of Medpace, Inc., a global full-service clinical contract research organization (CRO) to conduct its clinical trial in locally advanced, inoperable pancreatic cancer (LAPC), and with the recent news that the live cells necessary for that clinical trial ...
Read More →
23
JAN
Share
PharmaCyte’s Clinical Trial in Pancreatic Cancer Serves as Proving Ground for Its One of a Kind Cell Encapsulation Technology
Written by Ι Stock Market Media — June 6, 2018
PharmaCyte Biotech, Inc. (OTCQB: PMCB) is closing in on what will be a landmark event in this small company’s history—a clinical trial in the United States under the watchful eye of the most powerful drug regulatory agency in the world, the U.S. Food and Drug Administration (FDA). It would be the company’s first clinical trial ever and could serve as the event that changes the way solid cancerous tumors are treated, ...
Read More →
6
JUN
Share
PharmaCyte Biotech Releases Video Highlighting Diabetes Treatment Development Program
SILVER SPRING, Md., Dec. 15, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has released a new video that highlights PharmaCyte’s diabetes treatment development program. PharmaCyte invited Stock Market Media Group to sit in on its 2nd Annual International Diabetes Consortium in Vienna, Austria, to document PharmaCyte’s story related to the development of its treatment ...
Read More →
15
DEC
Share
